Overview

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

Status:
Recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir resistant or acyclovir susceptible mucocutaneous HSV infection, treated with pritelivir 100 mg once daily (following a loading dose of 400 mg as first dose to rapidly reach steady-state plasma concentration) or foscarnet 40 mg/kg every 8 hours or 60 mg/kg every 12 hours.

Phase:

Phase 3

Details

Lead Sponsor:

AiCuris Anti-infective Cures GmbH

Collaborator:

Medpace, Inc.

Treatments:

Acyclovir
Foscarnet
Phosphonoacetic Acid
Pritelivir